Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the growing number of patients affected with lymphoma and multiple myeloma is also fueling the growth of the global retinal vein occlusion market.
The Global Retinal Vein Occlusion Market is expected to grow at a CAGR of 11.2% during the forecast period 2017-2023.
According to the Centers for Disease Control and Prevention, in 2014, around 47,135 people were diagnosed with leukemia and out of which 23,564 people died from the disease. According to the American Cancer Society, around 4% of all cancers in the United States is lymphoma, additionally, it is estimated that in 2018, about 74,680 people including both adults and children will be diagnosed with lymphoma and around 19,910 people will die from this. According to the American Cancer Society, the risk of acquiring multiple myeloma in the United States is 1 in 143 that is 0.7%, additionally, it is estimated that in 2018, around 30,770 new cases are likely to be diagnosed and the estimated death toll would be around 12,770.
Taste the market data and market information presented through more than 150 market data tables and figures spread over 206 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “retinal vein occlusion market research report–Global forecast till 2023.”
Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/5377 .
Major Players in the Retinal Vein Occlusion Market
Some of the key players in this market are Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, GlaxoSmithKline Plc, IRIDEX Corporation, Novartis, Quantel Medical Inc, Topcon Medical Systems, Inc., ZEISS, Lumenis, Sanofi Aventis, Valeant Pharmaceuticals, Alimera Sciences, Fovea Pharmaceuticals SA, Icon Biosciences, Suzuken Co.Ltd, Genentech, Inc., Ranbaxy Pharmaceuticals, Johnson & Johnson Services, Inc, Teva Pharmaceutical, Pfizer Inc., Astrazeneca, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB and others.
- The Global Retinal Vein Occlusion Market was estimated to USD 7,557.52 million in 2016
- Fundoscopic examination is the fastest growing segment, which is projected to grow at a CAGR of 11.6% during the forecast period from 2017-2023
- The Americas has captured the largest market globally and is expected to reach USD 6,018.16 million by 2023
- Asia Pacific is the fastest growing region across the globe and expected to grow at a rate of CAGR 11.4% during the forecast period
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment and end user.
On the basis the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion.
On the basis of the condition, it is segmented into non-ischemic and ischemic.
Based on the diagnosis, it is segmented into optical coherence tomography (OCT), fundoscopic examination, fluorescein angiography, and others.
Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/5377 .
On the basis of treatment, it is segmented into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation, and others.
On the basis of the end users, it is segmented into hospitals and clinics, research & academics centers, and others.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312